Dinesh de Alwis has over 19 years of global experience in the pharmaceutical industry, working with large and small molecules from discovery to loss of data exclusivity. He is currently an Executive Director of Quantitative Pharmacology and Pharmacometrics (QP2), PPDM at Merck Research Laboratories in New Jersey, where he is responsible for Quantitative Pharmacology in Oncology, Immunology, Vaccines and Neuroscience compounds. Since he joined Merck in 2012, he has been actively involved in the development of several compounds and played a significant part in the dose finding and registration of KEYTRUDA® for IPI refractory metastatic melanoma. He previously held several leadership and scientific roles at Eli Lilly and Company (1997 – Jan 2012), in the UK. He headed a group of PK/PD scientists (since 2004) and was the lead PK/PD Scientist for several compounds (therapeutic areas of neuroscience, cardiovascular, oncology) from pre-clinical to phase III studies for over 14 years. Dr de Alwis has co-authored over 30 publications in peer-reviewed journals with over 1000 citations and is on the editorial board of a journal. He is also on the scientific committee of the Population Approach Group in Europe (PAGE) since 2003. Dr de Alwis received his PhD from the University of Manchester (1997), UK in the field of Population PK/PD.